Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial. Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six‐item subscales of the Hamilton Depression Scale (HAM‐D 17) and of the Inventory of Depressive Symptomatology (IDS‐C 30), referred to as HAM‐D 6 and IDS‐C 6, were focussed on pure antidepressive effect. Side‐effects (tolerable vs. intolerable) and quality of life were measured using patient‐administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion‐SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion‐SR was superior (P = 0.05) on the HAM‐D 6, IDS‐C 6, and IDS‐C 30, but not on the HAM‐D 17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion‐SR than by buspirone (P = 0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES‐Q) showed a trend (P = 0.10) from baseline to endpoint of a superiority for bupropion‐SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion‐SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 5×
“In our analysis, we considered whether to look at the intention-to-treat population used in the previous STAR*D publication (8) i.”
BackgroundMethodResultInfluentialSelf-citationThe heterogeneity of the depressive syndrome: when numbers get serious
Østergaard, S. D., Jensen, S. O. W., & Bech, P. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01744.x · Cited by 287 · cited 1×
“Such core items of depression are important when evaluating the dimensional approach to clinical depression (16, 17).”
BackgroundSelf-citation
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“This, however, was based on a difference in the depression rating scales of one to two points (Bech et al. 2012).”
BackgroundSerotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Carrozzino, D., Patierno, C., Fava, G. A., & Guidi, J. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506879 · Cited by 263
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457131 · Cited by 134
Self-citationClinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89
“Figure 3 illustrates an attempt at evaluating outcomes using a multidimensional approach (Bech, 2009; Bech, Fava, Trivedi, Wisniewski, & Rush, 2012).”
Self-citation
Metadata
- Authors
- Bech, P., Fava, M., Trivedi, M. H., Wisniewski, S. R., & Rush, A. J.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2011-11-12
- Volume
- 125
- Issue
- 4
- Pages
- 342-348
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W1933676799
- Cited by
- 46
- References
- 3
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial. https://app.cochat.ai/papers/10.1111/j.1600-0447.2011.01791.x
- The paper
- Bech, P., Fava, M., Trivedi, M. H., Wisniewski, S. R., & Rush, A. J. (2012). Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2011.01791.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.